Literature DB >> 33716922

A Retrospective Longitudinal Study in a Cohort of Children With Dyskinetic Cerebral Palsy Treated With Tetrabenazine.

Roberta Scalise1,2, Giuseppina Sgandurra1,3, Valentina Menici1, Nicola Capodagli1,3, Roberta Di Pietro1, Domenico M Romeo4, Francesca Sini4, Emanuela Pagliano5, Maria Foscan5, Giovanni Cioni1,3, Roberta Battini1,3.   

Abstract

Tetrabenazine has been studied with a variety of hyperkinetic movement disorders, but there is limited and empirical literature on the potential efficacy of tetrabenazine in children with dyskinetic cerebral palsy (DCP). The purpose of this study was to evaluate the efficacy of tetrabenazine in a sample of children with DCP using the Movement Disorders-Childhood Rating Scale 4-18 Revised (MD-CRS 4-18 R). The study is a multicenter retrospective longitudinal study in which the participants were selected from the databases of each Center involved, according to detailed inclusion criteria. The study was performed on 23 children and adolescents (19 male and 4 females; mean age 8.28 years, SD 3.59) with DCP having been evaluated before starting the treatment (baseline), after 6 and 12 months of treatment and in a sub-cohort after >2 years follow-up. A linear mixed model was used to evaluate the effects of the different timings on each MD-CRS 4-18 R Index (Index I, Index II, and Global Index) adding age and type of movement disorder as random effect. A significant clinical improvement related to a reduction of MD-CRS 4-18 R Indexes was detected between the baseline and after 6 and 12 months of treatment. Findings support the efficacy of tetrabenazine in children with DCP through a standardized outcome measure (MD-CRS 4-18 R) and confirm the use of this scale as a suitable tool to detect changes in further randomized clinical trials.
Copyright © 2021 Scalise, Sgandurra, Menici, Capodagli, Di Pietro, Romeo, Sini, Pagliano, Foscan, Cioni and Battini.

Entities:  

Keywords:  MD-CRS 4–18 R; children; dyskinetic cerebral palsy; movement disorder; tetrabenazine

Year:  2021        PMID: 33716922      PMCID: PMC7953156          DOI: 10.3389/fneur.2021.612429

Source DB:  PubMed          Journal:  Front Neurol        ISSN: 1664-2295            Impact factor:   4.003


  20 in total

1.  Tetrabenazine for involuntary movement disorders.

Authors:  D Kingston
Journal:  Med J Aust       Date:  1979-06-30       Impact factor: 7.738

Review 2.  Pharmacological and neurosurgical interventions for managing dystonia in cerebral palsy: a systematic review.

Authors:  Darcy Fehlings; Leah Brown; Adrienne Harvey; Kate Himmelmann; Jean-Pierre Lin; Alexander Macintosh; Jonathan W Mink; Elegast Monbaliu; James Rice; Jessica Silver; Lauren Switzer; Ilana Walters
Journal:  Dev Med Child Neurol       Date:  2018-02-06       Impact factor: 5.449

3.  Movement disorder-childhood rating scale: reliability and validity.

Authors:  Roberta Battini; Giuseppina Sgandurra; Elisa Petacchi; Andrea Guzzetta; Roberta Di Pietro; Maria T Giannini; Vincenzo Leuzzi; Eugenio Mercuri; Giovanni Cioni
Journal:  Pediatr Neurol       Date:  2008-10       Impact factor: 3.372

4.  Responsiveness of the MD-childhood rating scale in dyskinetic cerebral palsy patients undergoing anticholinergic treatment.

Authors:  Roberta Battini; Manuela Casarano; Giuseppina Sgandurra; Ilaria Olivieri; Roberta Di Pietro; Domenico M Romeo; Eugenio Mercuri; Giovanni Cioni
Journal:  Eur J Paediatr Neurol       Date:  2014-06-19       Impact factor: 3.140

Review 5.  Efficacy of oral pharmacological treatments in dyskinetic cerebral palsy: a systematic review.

Authors:  Riccardo Masson; Emanuela Pagliano; Giovanni Baranello
Journal:  Dev Med Child Neurol       Date:  2017-09-05       Impact factor: 5.449

Review 6.  Clinical presentation and management of dyskinetic cerebral palsy.

Authors:  Elegast Monbaliu; Kate Himmelmann; Jean-Pierre Lin; Els Ortibus; Laura Bonouvrié; Hilde Feys; R Jeroen Vermeulen; Bernard Dan
Journal:  Lancet Neurol       Date:  2017-09       Impact factor: 44.182

7.  Surveillance of cerebral palsy in Europe: a collaboration of cerebral palsy surveys and registers. Surveillance of Cerebral Palsy in Europe (SCPE).

Authors: 
Journal:  Dev Med Child Neurol       Date:  2000-12       Impact factor: 5.449

8.  Tetrabenazine (Xenazine), An FDA-Approved Treatment Option For Huntington's Disease-Related Chorea.

Authors:  Tatiana Yero; Jose A Rey
Journal:  P T       Date:  2008-12

9.  GNAO1 encephalopathy: Broadening the phenotype and evaluating treatment and outcome.

Authors:  Federica Rachele Danti; Serena Galosi; Marta Romani; Martino Montomoli; Keren J Carss; F Lucy Raymond; Elena Parrini; Claudia Bianchini; Tony McShane; Russell C Dale; Shekeeb S Mohammad; Ubaid Shah; Neil Mahant; Joanne Ng; Amy McTague; Rajib Samanta; Gayatri Vadlamani; Enza Maria Valente; Vincenzo Leuzzi; Manju A Kurian; Renzo Guerrini
Journal:  Neurol Genet       Date:  2017-03-21

10.  Delineation of the movement disorders associated with FOXG1 mutations.

Authors:  Apostolos Papandreou; Ruth B Schneider; Erika F Augustine; Joanne Ng; Kshitij Mankad; Esther Meyer; Amy McTague; Adeline Ngoh; Cheryl Hemingway; Robert Robinson; Sophia M Varadkar; Maria Kinali; Vincenzo Salpietro; Margaret C O'Driscoll; S Nigel Basheer; Richard I Webster; Shekeeb S Mohammad; Shpresa Pula; Marian McGowan; Natalie Trump; Lucy Jenkins; Frances Elmslie; Richard H Scott; Jane A Hurst; Belen Perez-Duenas; Alexander R Paciorkowski; Manju A Kurian
Journal:  Neurology       Date:  2016-03-30       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.